All In Biotech

Drug Trial Radar · NCT06426485

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

A Multicenter, Randomized Withdrawal, Double-blind, Parallel, Placebo-controlled Design Clinical Trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets

Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 736 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

736

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Feb 28, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
May 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized withdrawal, double-blind, parallel, placebo-controlled design clinical trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets to evaluate the long-term efficacy and safety in the treatment of Chinese patients with depression.

Conditions

  • Major Depressive Disorder

Interventions

  • Toludesvenlafaxine Hydrochloride Sustained-release TabletsDrug

    orally once a day

  • placeboDrug

    orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to relapse.Time frame: from Baseline to week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.